Sandrine Compeyrot-Lacassagne

Dr. Sandrine Compeyrot-Lacassagne


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2014 in Trials
Verified
Journal Article
Open access
PDF file
TGThe SYCAMORE Trial Management Group
The SYCAMORE Trial Management Group
ARAthimalaipet V Ramanan
Athimalaipet V Ramanan
ADAndrew D Dick
Andrew D Dick
DBDiana Benton
Diana Benton
SCSandrine Compeyrot-Lacassagne
Sandrine Compeyrot-Lacassagne
MBMichael W Beresford
Michael W Beresford
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA are at risk of inflammation of the uvea in the eye (uveitis). Overall, 20% to 25% of paediatric uveitis is associated with JIA. Major risk factors for development of uveitis in JIA are oligoarticular pattern of arthritis, an age at onset of arthritis of less than seven years of age, and antinuclear antibody positivity. In the initial stages of mild to moderate inflammation the uveitis is asymptomatic. This has led to current practice of screening all children with JIA for uveitis. Approximately 12% to 38% of patients with JIA develop uveitis in seven years following onset of arthritis. In 30% to 50% of children with JIA-associated uveitis structural complications are present at diagnosis. Furthermore about 50% to 75% of those with severe uveitis will eventually develop visual impairment secondary to ocular complications such as cataract and glaucoma. Defining the severity of inflammation and structural complications in uveitis patients is now possible following Standardised Uveitis Nomenclature (SUN) guidelines, and modified to incorporate the consensus of end point and outcome criteria into the design of randomised trials. Despite current screening and therapeutic options (pre-biologics) 10% to 15% of children with JIA-associated uveitis may develop bilateral visual impairment and certified legally blind. To date, there remains no controlled trial evidence of benefits of biologic therapy.

5 August 2013 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
SUSaik Urien
Saik Urien
CBChristophe Bardin
Christophe Bardin
BBBrigitte Bader-Meunier
Brigitte Bader-Meunier
RMRichard Mouy
Richard Mouy
SCSandrine Compeyrot-Lacassagne
Sandrine Compeyrot-Lacassagne
PQPierre Quartier
Pierre Quartier
Anakinra pharmacokinetics and pharmacodynamics were investigated in children and adolescents treated for systemic-onset juvenile idiopathic arthritis (SJIA) and autoinflammatory syndromes.

14 June 2019 in Rheumatology
Verified
Journal Article
Closed access
PDF file
PKParichat Khaosut
Parichat Khaosut
CPClarissa Pilkington
Clarissa Pilkington
LWLucy R Wedderburn
Lucy R Wedderburn
SCSandrine Compeyrot-Lacassagne
Sandrine Compeyrot-Lacassagne
Rheumatology key message. Definition of JDM-scleroderma overlap phenotype is important to tailor patients’ management.